"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine"
NEJM
http://www.nejm.org/doi/full/10.1056/NEJMoa1304369?query=featured_home
"CONCLUSIONS

In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.)"